Imaging-based evaluation of pathogenicity by novel DNM2 variants associated with centronuclear myopathy

Kenshiro Fujise, Mariko Okubo, Tadashi Abe, Hiroshi Yamada, Kohji Takei, Ichizo Nishino, Tetsuya Takeda, Satoru Noguchi

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


A centronuclear myopathy (CNM) is a group of inherited congenital diseases showing clinically progressive muscle weakness associated with the presence of centralized myonuclei, diagnosed by genetic testing and muscle biopsy. The gene encoding dynamin 2, DNM2, has been identified as a causative gene for an autosomal dominant form of CNM. However, the information of a DNM2 variant alone is not always sufficient to gain a definitive diagnosis as the pathogenicity of many gene variants is currently unknown. In this study, we identified five novel DNM2 variants in our cohort. To establish the pathogenicity of these variants without using clinicopathological information, we used a simple in cellulo imaging-based assay for T-tubule-like structures to provide quantitative data that enable objective determination of pathogenicity by novel DNM2 variants. With this assay, we demonstrated that the phenotypes induced by mutant dynamin 2 in cellulo are well correlated with biochemical gain-of-function features of mutant dynamin 2 as well as the clinicopathological phenotypes of each patient. Our approach of combining an in cellulo assay with clinical information of the patients also explains the course of a disease progression by the pathogenesis of each variant in DNM2-associated CNM.

Original languageEnglish
Pages (from-to)169-179
Number of pages11
JournalHuman mutation
Issue number2
Publication statusPublished - Feb 2022

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Imaging-based evaluation of pathogenicity by novel DNM2 variants associated with centronuclear myopathy'. Together they form a unique fingerprint.

Cite this